Premium
Adenoviral Transfer of the Melanoma Differentiation Gene‐7 (mda‐7) Induces Increased Expression of the Ryanodine Receptor (RyR) in (LnCaP) Prostate Cancer Cells
Author(s) -
Williams Carleta,
Naikadie Saphir,
Li Rong,
Fisher Paul,
DePass Anthony
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.5.a256
Subject(s) - ryanodine receptor , cancer research , lncap , melanoma , cancer cell , biology , endoplasmic reticulum , prostate cancer , microbiology and biotechnology , cancer , genetics
Melanoma Differentiation Associated Gene‐7/Interleukin‐24 (mda‐7/IL‐24) specifically induces apoptosis in cancer cells. It was discovered using a subtraction hybridization screen of human melanoma (HO‐1) cells whereby growth arrest terminal differentiation were induced by treatment with a combination of INFβ and Mezerein. Its anti tumor effects, modulation of immune responses, synergy with radiation and its ability to discriminate between normal and cancer cells and success in clinical trials demonstrates tremendous promise in its potential as an agent for differentiation therapy to treat cancer. Although its anticancer effects are widely known, details of the mechanisms necessary for its activity remain to be elucidated. RT PCR was used to examine the impact of mda7 treatment of human prostate cancer cells (LnCaP) on the expression of RyR that regulates intracellular calcium release from the endoplasmic reticulum, often as part of a signaling event. We report that with mRNA analysis of RT‐PCR, within 24 and 48 hours of mda7 treatment there is a distinctive increase in expression on RyR compared to the expression of cells that were not treated with mda7. Western blot analysis shows protein expression of MDA7 after 24 and 48 hours treatments. Protein expression analysis of the RyR provides evidence that MDA‐7 treatment of cells causes an increase of RyR expression.